(clarifies that it is Analysguiden)Aktiespararnas Analysguiden retains the justified value range for the medtech company Redsense Medical at SEK 6–9 per share. The analysis firm believes that the revised pricing structure, increased end-customer volumes in the US, and potential European contracts could lift revenue to around SEK 31 million in 2026.After the strong report for the first quarter, Analysguiden has also raised its assumption about the gross margin. Together with normalized operating expenses, this is expected to mean that Redsense Medical can approach break-even at the operating profit level already in 2026. A cash-flow-positive outcome is assessed as possible in 2027. At the same time, Analysguiden emphasizes that the valuation remains sensitive to the pace of growth in the US as well as a potential Clamp approval during 2026.